Secukinumab
Treatment for Ankylosing Spondylitis
Typical Dosage: 150mg or 300mg subcutaneous at week 0, 1, 2, 3, then every 4 weeks
Effectiveness
68%
Safety Score
60%
Clinical Trials
23
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
150mg or 300mg subcutaneous at week 0, 1, 2, 3, then every 4 weeks
Time to Effect
2-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$38,000
Monitoring:$500
Side Effect Mgmt:$500
Total Annual:$39,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$140,000/QALY
QALYs Gained
1.1
Outcome-Based Costs
Cost per Responder
$55,714
Cost per Remission
$130,000
Comparison vs Adalimumab
Cost Difference
+$8,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Secukinumab Outcomes
for Ankylosing Spondylitis
Efficacy Outcomes
Overall Effectiveness
+68%
Response Rate
+70%
Remission Rate
+30%
Common Side Effects
Nasopharyngitis
+18%
Upper respiratory tract infections
+15%
Diarrhea
+5%
Oral candidiasis
+2%
Sources:
Active Clinical Trials
2 active trials recruiting for Secukinumab in Ankylosing Spondylitis
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
NCT06905288RECRUITING
70 participants
OBSERVATIONAL
Busan, South Korea +1 more
Started: Apr 2, 2025
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT06833112NOT YET RECRUITINGPHASE4
10 participants
INTERVENTIONAL
Guiyang, China
Started: Feb 1, 2025
Completed Clinical Trials
15 completed trials for Secukinumab in Ankylosing Spondylitis
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
NCT02159053COMPLETEDPHASE3
350 participants
INTERVENTIONAL
Anniston, United States +89 more
Started: May 18, 2015
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
NCT02008916COMPLETEDPHASE3
226 participants
INTERVENTIONAL
Mobile, United States +56 more
Started: Jan 14, 2014
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
NCT02896127COMPLETEDPHASE3
458 participants
INTERVENTIONAL
Hefei, China +43 more
Started: Oct 18, 2016
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
NCT04156620COMPLETEDPHASE3
527 participants
INTERVENTIONAL
Irvine, United States +101 more
Started: Dec 11, 2019
Extension in AS: Sustainability of Benefits, Safety and Tolerability
NCT01863732COMPLETEDPHASE3
274 participants
INTERVENTIONAL
Portland, United States +55 more
Started: Nov 6, 2013
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
NCT01358175COMPLETEDPHASE3
371 participants
INTERVENTIONAL
Boise, United States +66 more
Started: Oct 1, 2011
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
NCT02763046COMPLETEDPHASE4
211 participants
INTERVENTIONAL
Bad Doberan, Germany +38 more
Started: May 31, 2016
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
NCT03350815COMPLETEDPHASE4
322 participants
INTERVENTIONAL
Jonesboro, United States +64 more
Started: Mar 13, 2018
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
NCT03259074COMPLETEDPHASE3
859 participants
INTERVENTIONAL
Mesa, United States +170 more
Started: Nov 30, 2017
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
NCT02750592COMPLETEDPHASE3
30 participants
INTERVENTIONAL
Kitakyushu, Japan +9 more
Started: Mar 22, 2016
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
NCT01649375COMPLETEDPHASE3
219 participants
INTERVENTIONAL
Mesa, United States +52 more
Started: Oct 18, 2012
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
NCT02696031COMPLETEDPHASE3
555 participants
INTERVENTIONAL
Birmingham, United States +138 more
Started: Apr 29, 2016
Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
NCT00809159COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Paradise Valley, United States +19 more
Started: Mar 1, 2009
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
NCT05155098COMPLETED
127 participants
OBSERVATIONAL
Songkhla, Thailand +9 more
Started: Mar 25, 2022
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
NCT03136861COMPLETEDPHASE3
383 participants
INTERVENTIONAL
Brussels, Belgium +65 more
Started: Jun 30, 2017
Showing 20 of 23 total trials